Chromosome Aberrations Clinical Trial
Official title:
Multi Centre Controlled Study on the Impact of Stem Cell Donation Either After Mobilisation With Granulocyte Colony Stimulating Factor or Bone Marrow Harvest on Unrelated Bone Marrow Donors.
Granulocyte Colony Stimulating Factor (GCSF) is used extensively as a means of mobilising
donor peripheral blood stem cells as an alternative to bone marrow harvesting for the
purpose of recipient stem cell transplantation. The principal objective of the research is
to study any longterm genetic effects of GCSF in the peripheral blood white cells of
unrelated blood stem cell donors.
The study subjects will be Retrospective and Prospective voluntary unrelated donors on the
Anthony Nolan Bone Marrow Registry being harvested at the Royal Free Hospital and University
College Hospital, London and British Bone Marrow Registry donors harvested at the Royal Free
Hospital and BUPA Glen Vale in Bristol.
All participants in the Prospective Arm will be asked to donate one 5−10ml sample of blood
at study entry prior to stem cell donation and further samples at 120 and 360 days post
donation. Those found to carry aneuploid cell clones at these time points will be asked for
a further 5−10ml blood sample at least twice − at the end of 24 months and 36 months
respectively. The Retrospective and Positive Control group will be asked to supply one
5−10ml sample of blood.
The aim of this study is to detect any genetic differences between bone marrow and PBSC
unrelated donors, post donation and confirm or refute the observations of "long-term genetic
or epigenetic effects" published by Nagler et al[Nagler,A. et al. Exp.Haem (2004)
32;122-30]. The employment of more sensitive methods such as iFISH and gene array analysis
to assess any permanent genetic changes, our primary objective, will make our study more
robust.
There will be two arms:
i) Retrospective arm - the peripheral blood of unrelated donors who donated 3 to 5 years
previously will be screened.
ii) Prospective arm - peripheral blood of unrelated donors will be examined prior to
donation and at 120 and 360 day's post-donation. In those found to have aneuploid changes at
these time points, there will be additional sampling at 24 and 36 months and if necessary
these donors will be followed up.
Each arm of the study will include 50 BM unrelated donors and 50 PBSC unrelated donors
giving a total sample population of around 200 unrelated donors. There will be one positive
control group of 50 patients with a range of haematological malignancies. The blood samples
taken from both BM and PBSC donors prior to donation will act as internal negative controls.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT00227253 -
Chromosome 18 Clinical Research Center
|
||
Recruiting |
NCT06141213 -
The Relationship Between Fetal Membrane Thickness and Fetal Chromosomal Aneuploidies
|